PropertyValue
?:abstract
  • Coronavirus disease (COVID-19) is a pandemic disease appeared in China in December 2019 and has since spread throughout the world The recent outbreak of acute respiratory infection is caused by a new type of coronavirus, named as (SARS-CoV-2) At the moment, there are no specific medications or vaccines to treat COVID-19 Recently, a combination of the antimalarial hydroxychloroquine (HCQ) and azithromycin (AZM) antibiotic is used effectively in treatment of COVID-19 The present article discusses the possibility of the development of a new cost-effective pharmaceutical product combing HCQ and AZM in management of coronavirus infections Such an approach would involve waiving of the in-vivo bioavailability and bioequivalence studies of the conventional oral dosage forms for emergency approval from regulatory affair authorities
is ?:annotates of
?:creator
?:journal
  • Journal_of_Pharmaceutical_Sciences_and_Research
?:license
  • unk
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:source
  • WHO
?:title
  • Proposing biowaver as a prompt tool for the new pharmaceutical products approval in management of coronavirus outbreaks
?:type
?:who_covidence_id
  • #627204
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/9ysqw9f6>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/9ysqw9f6>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all